Predominance of detrimental humoral immune responses to HIV-1 in AIDS patients with CD4 lymphocyte counts less than 400/mm3

Scandinavian Journal of Immunology

Volumn 45, Issue 1, 1997, Pages 103-111

  Mcdougall, B ^a   Nymark, M H ^a   Landucci, G ^b   Forthal, D ^b   Robinson Jr , W E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; LYMPHOCYTE COUNT; NATURAL KILLER CELL; PRIORITY JOURNAL;

EID: 0031012358     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-374.x     Document Type: Article

References (52)

1. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type I infection. N Engl J Med 1995;332:201-8.
2. Kent SJ, Corey L, Agy MB, Morton WR, McElrath MJ, Greenberg PD. Cytotoxic and proliferative T cell responses in HIV-1-infected Macaco nemestrina. J Clin Invest 1995;95:248-56.
3. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995; 332:228-32.
4. Pantaleo G, Menzo S, Vaccarezza M et al. Studies on subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995;332:209-16.
5. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virusspecific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-10.
6. Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type I syndrome. J Virol 1994; 68:4650-5.
7. Robert-Guroff M, Brown M, Gallo RC. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1985;316:72-4.
8. Robinson WE Jr, Mitchell WM. Neutralization and enhancement of in vitro and in vivo HIV and simian immunodeficiency virus infections. Aids 1990;4:S151-62.
9. Rasheed S, Norman GL, Gill PS, Meyer PR, Cheng L, Levine AM. Virus-neutralizing activity, serologic heterogeneity, and retrovirus isolation from homosexual men in the Los Angeles area. Virology 1986;150:1-9.
10. Sei Y, Tsang PH, Roboz JP, Sarin PS, Wallice JI, Bekesi JG. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double blind study. J Clin Immunol 1988;8:464-72.
11. Wendler I, Bienzle U, Hunsmann G. Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Hum Retroviruses 1987; 3:157-63.
12. Modrow S, Hoflacher B, Mellert W, Erfle V, Wahren B, Wolf H. Use of synthetic oligopeptides in identification and characterization of immunological functions in the amino acid sequence of the envelope protein of HIV-1. J Acquired Immune Def Syndromes 1989;2:21-7.
13. Wong MT, Warren RQ, Anderson SA et al. Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjects. J Inf Dis 1993;168:1523-7.
14. Scarlatti G, Leitner T, Hodara V et al. Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1. AIDS 1993;7:S45-S48.
15. Matthews TJ. Tenth Anniversary Perspectives on AIDS- dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses 1994;10:631-2.
16. Hanson CV. Meeting report - measuring vaccine-induced HIV neutralization: report of a workshop. AIDS Res Hum Retroviruses 1994;10:645-8.
17. Robinson WE Jr, Montefiori DC, Mitchell WM. Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 1990;175:600-4.
18. Banapour B, Sernatinger J, Levy JA. The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology 1986;152:268-71.
19. Dierich MP, Ebenbichler CF, Marschang P, Fust G, Thielens NM. Arlaud GJ. HIV and human complement: mechanisms of interaction and biological implication. Immunol Today 1993;14:435-40.
20. Spear GT, Sullivan BL, Takefman DM, Landay AL, Lint TF. Human immunodeticiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse, and guinea-pig sera; activation results in virus neutralization by virolysis. Immunology 1991;73:377-82.
21. Robinson WE Jr, Montefiori DC, Mitchell WM. Antibody dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988;i:790-4.
22. Thieblemont N, Haeffner-Cavaillon N, Ledur A, L'Age-Stehr J, Ziegler-Heitbrock HWL, Kazatchkine MD. CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin Exp Immunol 1993;92:106-13.
23. Tremblay M, Meloche S, Sekaly R-P, Wainberg MA. Complement receptor 2 mediates enhancement of human immunodeficiency virus type 1 infection in Epstein-Barr virus-carrying B cells. J Exp Med 1990;171:1791-6.
24. Fust G, Toth FD, Kiss J, Ujhelyi E, Nagy I, Banhegyi D. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. AIDS 1994;8:603-9.
25. Montefiori DC, Lefkowitz LB Jr, Keller RE, Holmberg V, Sandstrom E, Phair JP. Absence of a clinical correlation for complementmediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group. Aids 1991;5:513-7.
26. Montefiori DC, Robinson WE Jr, Hirsch VM, Modliszewski A, Mitchell WM, Johnson PR. Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol 1990;64:113-19.
27. Montefiori DC, Murphey-Corb M, Desrosiers RC, Daniel MD. Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. J Virol 1990;64:5223-5.
28. Mitchell WM, Torres J, Johnson PR et al. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques. Aids 1995;9:27-34.
29. Gardner M, Rosenthal A, Jennings M, Yee JA, Antipa L, Robinson E Jr. Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res Hum Retroviruses 1995;11:843-54.
30. Montefiori DC, Robinson WE Jr, Hirsch VM, Modliszewski A, Mitchell WM, Johnson PR. Antibody-dependent enhancement of SIV infection: further characterization and cross reactivity between macaque and sooty mangabey isolates. J Med Primatol 1990;19: 269-78.
31. Brenner BG, Gryllis C, Wainberg MA. Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. J Leuk Biol 1991;50:628-40.
32. Koup RA, Sullivan JL, Levine PH et al. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol 1989;63:584-90.
33. Tanneau F, McChesney M, Lopez O, Sansonetti P, Montagnier L, Riviere Y. Primary cytotoxicity against envelope glycoprotein of human immunodeficiency virus-1: evidence for antibody-dependent cellular cytotoxicity in vivo. J Inf Dis 1990;162:837-43.
34. Mitchell WM, Forti RL, Vogler LB, Lawton AR, Gregg CR. Spontaneous and interferon resistant natural killer cell anergy in AIDS. AIDS Res 1984;1:221-9.
35. Katz JD, Mitsuyasu R, Gottlieb MS, Lebow LT, Bonavida B. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity. J Immunol 1987;139:55-60.
36. Reddy M, Pinyavat N, Grieco MH. Interleukin 2 augmentation of natural killer cell activity in homosexual men with acquired immune deficiency syndrome. Infection Immunity 1984;44:339-43.
37. Rook AH, Masur H, Lane HC et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983;72:398-403.
38. Bobak DA, Frank MM, Tenner AJ. Characterization of C1q receptor expression on human phagocytic cells: effects of PDBu and FMLP. J Immunol 1986;136:4604-10.
39. Guan E, Burgess WH, Robinson SL, Goodman EB, McTigue KJ, Tenner AJ. Phagocytic cell molecules that bind the collagen-like region of C1q: involvement in the C1q-mediated enhancement of phagocytosis. J Biol Chem 1991;266:20345-55.
40. Connor RI, Mohri H, Cao Y, Ho DD. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency type 1-infected individuals. J Virol 1993;67:1772-7.
41. Putney SD, Matthews TJ, Robey WG et al. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science 1986;234:1392-5.
42. Montefiori DC, Robinson WE Jr, Schuffman SS, Mitchell WM. Evaluation of antiviral drugs and neutralizing antibodies against human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol 1988;26:231-5.
43. Robinson WE Jr, Montefiori DC, Gillespie DH, Mitchell WM. Complement-mediated, antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro increases HIV-1 RNA and protein synthesis and infectious virus production. J Acquired Immune Def Syndromes 1989;2:33-42.
44. Fischer E, Delibrias C, Kazatchkine MD. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 1991;146:865-9.
45. June RA, Landay K, Stefanik K, Lint TF, Spear GT. Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons. Immunology 1992;75: 59-65.
46. Sellheyer K, Schwarting R, Stein H. Isolation and antigenic profile of follicular dendritic cells. Clin Exp Immunol 1989;78:431-6.
47. Reynes M, Aubert JP, Cohen JHM et al. Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 1985;135:2687-94.
48. Montefiori DC, Pantaleo G, Fink LM et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Inf Dis 1996;173:60-7.
49. Rook AH, Lane HC, Folks T, McCoy S, Alter H, Fauci AS. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol 1987;138:1064-7.
50. Ljunggren K, Bottiger B, Biberfeld G, Karlson A, Fenyo E-M, Jondal M. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J Immunol 1987;139:2263-7.
51. Jenkins M, Landers D, Williams-Herman D et al. Association between anti-human immunodeficiency virus type 1 (HIV-1) antibody-dependent cellular cytotoxicity antibody titers at birth and vertical transmission of HIV-1. J Infect Dis 1994;170:308-12.
52. Kovacs JA, Baseler M, Dewar RJ et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995; 332:567-75.